Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amikacin (Insmed Incorporated)
- Development stage
- Approved
- Lead developer
- Insmed
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
Amikacin liposome inhalation suspension (ALIS), marketed as Arikayce, is a liposomal formulation of the aminoglycoside antibiotic amikacin developed by Insmed. It is specifically indicated for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). The drug is administered once daily via the Lamira Nebulizer System, which delivers the liposomal amikacin directly to the site of infection in the lungs. This targeted delivery allows for high local drug concentrations while minimizing systemic exposure and associated side effects such as ototoxicity and nephrotoxicity. ALIS was the first drug to be approved under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).
- Brand names
- Arikayce
- Other names
- amikacin liposome inhalation suspensionamikacin sulfate
02
Targets
Bacterial Ribosome
Beyond the preview
Go deeper on amikacin (Insmed Incorporated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amikacin (Insmed Incorporated).